Boulding Mark Elliott 4

What Happened

• Mark Elliott Boulding, Executive Vice President and Chief Legal Officer of PTC Therapeutics (PTCT), sold a total of 3,019 shares in open-market transactions on February 19, 2026, generating about $209,763. The sales were executed in four trades: 588 shares at $68.54 ($40,302); 1,629 shares at $69.82 ($113,737); 212 shares at $68.54 ($14,530); and 590 shares at $69.82 ($41,194). These were sales (not purchases) and therefore are generally treated as routine insider selling rather than a bullish signal.

Key Details

• Transaction date: February 19, 2026 (reported on Form 4 filed Feb 23, 2026). Filing appears timely (filed within required two business days).
• Trade prices/ranges: reported weighted prices $68.54 (trades executed across $67.99–$68.93) and $69.82 (trades executed across $69.52–$70.18); reporting person will provide per-trade breakdown upon SEC/issuer/shareholder request (see footnotes).
• Plan: Transactions were effected pursuant to a written Rule 10b5-1 trading plan adopted by Mr. Boulding on December 4, 2024.
• Shares owned after transaction: not specified in the excerpt provided.
• Total proceeds: ≈ $209,763 for 3,019 shares sold.

Context

• 10b5-1 plans are pre-arranged trading programs that allow insiders to sell on a scheduled basis; sales under such plans are often considered routine and reduce the informational value of the transaction about the insider’s view of the company. For retail investors, purchases usually carry more weight as potential positive signals than routine sales.